Q4-2019 Pharmacy & Infusion Services Update – A landmark transaction between Diplomat and Optum Rx defined the final quarter of 2019, resulting in the exit of the largest independent specialty pharmacy in the U.S.
Pharmaceutical Services: Spotlight on Tech-Enabled Clinical Development – The shift of development dollars to biologics and medicines for smaller, targeted populations is creating opportunities for outsourcing partners with the expertise as well as flexibility to work with midsize and emerging biopharmaceutical companies.
Q2-2019 Pharmacy Infusion Services Update – Transaction activity occurred within multiple sub-sectors of pharmacy services including LTC, infusion therapy, and specialty. Given the historical and future growth trajectory of the space, consolidation and investment activity is expected to continue for the foreseeable future.
Consolidation in Outsourced Pharmaceutical Services– Contract Research Organizations (CROs) and Contract Development & Manufacturing Organizations (CDMOs) are utilizing strategic mergers, acquisitions, and private equity partnerships to capitalize on tailwinds in the outsourced pharmaceutical services sector.
Q1-2019 Pharmacy Services Update – Private equity investment and M&A continued to reshape the pharmacy and infusion services sectors in the first quarter of 2019. Despite a recent wave of vertical integration between payors, PBMs and providers in the latter half of 2018, large-scale acquisitions have and will continue to occur as stakeholders expand their core competencies.